BRAF and melanoma: Among the 125 patients enrolled, 76 BRAFV600 patients were asymptomatic MBM and with no previous local brain therapy, (cohort A); 16 BRAFV600 patients were asymptomatic MBM and with previous local brain therapy (cohort B); and 16 BRAFV600D/K/R patients were asymptomatic MBM with or without previous local therapy (cohort C) and 17 BRAF V600D/K/R symptomatic melanoma brain metastases with or without previous local brain therapy, and an ECOG performance status of 0, 1, or 2 (cohort D).